Madrigal Pharmaceuticals, Inc. (MDGL) P/E Ratio History
Deep ValueTrading at -31.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2009–2010
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Madrigal Pharmaceuticals, Inc. (MDGL) trades at a price-to-earnings ratio of -31.1x, with a stock price of $399.63 and trailing twelve-month earnings per share of $-5.13.
The current P/E is 2052% below its 5-year average of 1.6x. Over the past five years, MDGL's P/E has ranged from a low of 1.0x to a high of 2.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 25.1x, MDGL trades at a 224% discount to its sector peers. The sector includes 229 companies with P/E ratios ranging from 0.0x to 195.0x.
Relative to the broader market, MDGL trades at a notable discount to the S&P 500 median P/E of 26.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MDGL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MDGL Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
MDGL P/E vs Peers
MASH & Liver Drugs peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 51.0 | - | -4% | |
| $12B | 40.5Lowest | 1.76Best | -25% | |
| $21B | 66.9 | - | +207%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
MDGL Historical P/E Data (2009–2010)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2010 Q2 | Jun 30 2010 | $94.50 | $99.43 | 1.0x | -40% |
| FY2010 Q1 | Mar 31 2010 | $150.85 | $98.52 | 1.5x | -4% |
| FY2009 Q4 | - | $177.10 | $82.63 | 2.1x | +35% |
| FY2009 Q3 | Sep 30 2009 | $108.50 | $62.05 | 1.7x | +10% |
Average P/E for displayed period: 1.6x
MDGL Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
17+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MDGL — Frequently Asked Questions
Quick answers to the most common questions about buying MDGL stock.
What is MDGL's P/E ratio?
Madrigal Pharmaceuticals, Inc. (MDGL) trailing twelve-month P/E ratio is -31.1x, based on TTM diluted EPS of $-5.13. The 5-year average P/E is 1.6x and the historical range spans 1.0x to 2.1x.
Is MDGL stock overvalued or undervalued?
MDGL trades at -31.1x P/E, below its 5-year average of 1.6x. At the 0th percentile of its historical range (1.0x–2.1x), the stock is priced at a discount to its own history.
Is MDGL stock expensive?
No, MDGL is not expensive on a historical basis. The current P/E of -31.1x is below the 5-year average of 1.6x and sits at the 0th percentile of its valuation range.
What is MDGL's historical P/E range?
Over the past 5 years, MDGL's P/E ratio has ranged from 1.0x to 2.1x, with a median of 1.7x and an average of 1.6x. The current P/E of -31.1x places the stock at the 0th percentile of this range. Full historical data spans 2009–2010.
How does MDGL's P/E compare to the S&P 500?
MDGL trades at -31.1x P/E versus the S&P 500 median of 26.3x. The 218% discount to the market suggests lower growth expectations or perceived higher risk.
How does MDGL's valuation compare to Healthcare peers?
Madrigal Pharmaceuticals, Inc. P/E of -31.1x compares to the Healthcare sector median of 25.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is MDGL's PEG ratio?
MDGL PEG ratio is N/A, based on a P/E of -31.1x and EPS growth of 41.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is MDGL's earnings yield?
MDGL earnings yield is N/A, the inverse of its -31.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.